Physician profile
Robin Luttrell
NPI 1629442470
$1,357.74
in general payments reported to CMS, 2019-2025
14 companies · $928 in 2025
The $928 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $430 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $270.21 | 2024-2025 | Xtampza, Belbuca |
| Globus Medical, INC. | $186.23 | 2025 | Senza |
| Nevro Corp. | $172.71 | 2024 | Senza |
| Abbott Laboratories | $166.76 | 2024-2025 | Proclaim, Eterna, Exclaim |
| Biotronik Nro, INC. | $123.23 | 2025 | Prospera |
| Medtronic, INC. | $114.64 | 2024-2025 | Synchromedii, Inceptiv, Kyphon Express II Kyphopak Tray |
| Tersera Therapeutics LLC | $89.46 | 2024-2025 | Prialt |
| Averitas Pharma INC. | $79.25 | 2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.63 | 2024-2025 | Relistor |
| Mml US, INC. | $30.97 | 2025 | Reactiv8 |
| Ibsa Pharma INC. | $23.12 | 2025 | Tirosint, Licart, Flector |
| Fidia Pharma USA INC. | $20.52 | 2024 | Hymovis |
| Kyowa Kirin, INC. | $19.96 | 2024 | Crysvita |
| Vertex Pharmaceuticals Incorporated | $16.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Luttrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.